According to a recent LinkedIn post from Latigo Biotherapeutics, the company is bringing Sara Bonstein onto its Board of Directors and assigning her as Chair of the Audit Committee. The post highlights her more than two decades of financial and operational experience in biotech, including her current position as CFO of Insmed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Bonstein’s background in capital strategy, governance, and scaling organizations is expected to support Latigo’s efforts to advance its pipeline and grow its non-opioid pain portfolio. For investors, this board appointment may signal a focus on strengthening financial oversight, capital markets readiness, and governance as the company moves into a more growth-oriented phase.
Given her active CFO role at a publicly traded biotech, Bonstein’s involvement could enhance Latigo’s credibility with prospective investors and partners. It may also indicate preparation for future financing activities or a potential public-market pathway, while underscoring an emphasis on disciplined capital allocation in the competitive non-opioid pain management space.